European Parliament vote advances EU–US tariff implementation

Posted on 07.04.2026

On 26 March 2026, the European Parliament approved two legislative proposals to implement the tariff-related commitments of the EU–US trade deal agreed in July 2025 (Turnberry deal), marking an important milestone in the process.

In a plenary vote, Members of the European Parliament backed the measures by a wide margin. The proposals, tabled by the European Commission, provide for adjustments to customs duties and tariff quotas for certain US-origin goods, as well as the reduction or non-application of EU duties on specified products.

For the medical technology sector, the removal or reduction of tariffs on US-origin industrial goods is particularly relevant. The measures cover devices under HS Chapter 90, as well as a broader range of industrial inputs used across the medical technology value chain. This may translate into lower landed costs for medical devices, components, machinery and other inputs used in production and distribution in the EU.

The European Parliament’s position also introduced a number of conditions to the agreement, including safeguard clauses allowing for the suspension of the deal in case of non-compliance as well as sunset and conditionality mechanisms to ensure implementation of commitments on both sides.

Following the vote, the file will move to trilogue negotiations with the Council, expected to begin in April 2026. Final adoption could follow later in the spring, subject to agreement between the co-legislators.

Ahead of the negotiations, MedTech Europe will continue to engage with policymakers on both the EU and US side to highlight the importance of prioritising medical technologies and their essential inputs in future tariff relief discussions in line with the commitments set out in the EU–US joint statement.

For more information, please contact Clare Birmingham, Manager International Affairs.